Hubei Guangji Pharmaceutical Co Ltd Market Cap ($281.89 Million)
Market Cap & Net Worth: Hubei Guangji Pharmaceutical Co Ltd (000952)
Hubei Guangji Pharmaceutical Co Ltd market cap. Hubei Guangji Pharmaceutical Co Ltd (SHE:000952) has a market capitalization of $281.89 Million (CN¥1.93 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #14856 globally and #4368 in its home market, demonstrating a -4.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hubei Guangji Pharmaceutical Co Ltd's stock price CN¥5.60 by its total outstanding shares 343999939 (344.00 Million). Also see Hubei Guangji Pharmaceutical Co Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Hubei Guangji Pharmaceutical Co Ltd Market Cap History (2015–2026)
Hubei Guangji Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows change from $936.16 Million to $281.89 Million (-5.57% CAGR). Check 000952 stock price for real-time trading data and today's change.
Hubei Guangji Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hubei Guangji Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Hubei Guangji Pharmaceutical Co Ltd (000952) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.57x
Hubei Guangji Pharmaceutical Co Ltd's market cap is 0.57 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $801.84 Million | $714.72 Million | $141.84 Million | 1.12x | 5.65x |
| 2017 | $584.08 Million | $801.56 Million | $105.21 Million | 0.73x | 5.55x |
| 2018 | $407.50 Million | $843.83 Million | $171.73 Million | 0.48x | 2.37x |
| 2019 | $390.69 Million | $731.34 Million | $86.94 Million | 0.53x | 4.49x |
| 2020 | $369.98 Million | $688.17 Million | $74.65 Million | 0.54x | 4.96x |
| 2021 | $390.88 Million | $785.57 Million | $110.11 Million | 0.50x | 3.55x |
| 2022 | $385.59 Million | $797.64 Million | $50.33 Million | 0.48x | 7.66x |
| 2023 | $402.20 Million | $737.82 Million | -$140.25 Million | 0.55x | N/A |
| 2024 | $311.09 Million | $638.80 Million | -$295.29 Million | 0.49x | N/A |
| 2025 | $353.88 Million | $623.97 Million | -$404.49 Million | 0.57x | N/A |
Competitor Companies of 000952 by Market Capitalization
Companies near Hubei Guangji Pharmaceutical Co Ltd in the global market cap rankings as of November 5, 2026. Also see how large is Hubei Guangji Pharmaceutical Co Ltd's balance sheet for a full breakdown of the balance sheet.
Key companies related to Hubei Guangji Pharmaceutical Co Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #12 globally with a market cap of $1.06 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #43 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #12 | Eli Lilly and Company | NYSE:LLY | $1.06 Trillion | $1417.99 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $276.32 |
| #43 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $294.83 |
Market Capitalization of Hubei Guangji Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Hubei Guangji Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Hubei Guangji Pharmaceutical Co Ltd's market cap moved from $936.16 Million to $ 281.89 Million, with a yearly change of -5.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥281.89 Million | -20.34% |
| 2025 | CN¥353.88 Million | +13.75% |
| 2024 | CN¥311.09 Million | -22.65% |
| 2023 | CN¥402.20 Million | +4.31% |
| 2022 | CN¥385.59 Million | -1.35% |
| 2021 | CN¥390.88 Million | +5.65% |
| 2020 | CN¥369.98 Million | -5.30% |
| 2019 | CN¥390.69 Million | -4.12% |
| 2018 | CN¥407.50 Million | -30.23% |
| 2017 | CN¥584.08 Million | -27.16% |
| 2016 | CN¥801.84 Million | -14.35% |
| 2015 | CN¥936.16 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Hubei Guangji Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $281.89 Million USD |
| MoneyControl | $281.89 Million USD |
| MarketWatch | $281.89 Million USD |
| marketcap.company | $281.89 Million USD |
| Reuters | $281.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hubei Guangji Pharmaceutical Co Ltd
Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, pharmaceutical preparations, and feed additives in China and internationally. The company also exports its products. Hubei Guangji Pharmaceutical Co., Ltd. was founded in 1969 and is based in Wuxue, China.